These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 19730388)
1. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. Dougherty DD; Jameson M; Deckersbach T; Loh R; Thompson-Hollands J; Jenike M; Keuthen NJ Int Clin Psychopharmacol; 2009 Nov; 24(6):306-11. PubMed ID: 19730388 [TBL] [Abstract][Full Text] [Related]
2. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Rabinowitz I; Baruch Y; Barak Y Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508 [TBL] [Abstract][Full Text] [Related]
3. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment. Saxena S; Maidment KM; Vapnik T; Golden G; Rishwain T; Rosen RM; Tarlow G; Bystritsky A J Clin Psychiatry; 2002 Jan; 63(1):21-7. PubMed ID: 11838621 [TBL] [Abstract][Full Text] [Related]
4. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder. Dougherty DD; Corse AK; Chou T; Duffy A; Arulpragasam AR; Deckersbach T; Jenike MA; Keuthen NJ Int J Neuropsychopharmacol; 2015; 18(2):. PubMed ID: 25637377 [TBL] [Abstract][Full Text] [Related]
5. Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report. Mukaddes NM; Abali O; Kaynak N Psychiatry Clin Neurosci; 2003 Aug; 57(4):405-8. PubMed ID: 12839522 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074 [TBL] [Abstract][Full Text] [Related]
8. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Feusner JD; Kerwin L; Saxena S; Bystritsky A Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653 [TBL] [Abstract][Full Text] [Related]
9. Outcome predictors for severe obsessive-compulsive patients in intensive residential treatment. Stewart SE; Yen CH; Stack DE; Jenike MA J Psychiatr Res; 2006 Sep; 40(6):511-9. PubMed ID: 16229857 [TBL] [Abstract][Full Text] [Related]
10. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Koran LM; Bromberg D; Hornfeldt CS; Shepski JC; Wang S; Hollander E Compr Psychiatry; 2010; 51(4):373-9. PubMed ID: 20579510 [TBL] [Abstract][Full Text] [Related]
11. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. Tollefson GD; Birkett M; Koran L; Genduso L J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493 [TBL] [Abstract][Full Text] [Related]
14. A pilot study of moderate-intensity aerobic exercise for obsessive compulsive disorder. Brown RA; Abrantes AM; Strong DR; Mancebo MC; Menard J; Rasmussen SA; Greenberg BD J Nerv Ment Dis; 2007 Jun; 195(6):514-20. PubMed ID: 17568300 [TBL] [Abstract][Full Text] [Related]
15. Electroacupuncture for refractory obsessive-compulsive disorder: a pilot waitlist-controlled trial. Zhang ZJ; Wang XY; Tan QR; Jin GX; Yao SM J Nerv Ment Dis; 2009 Aug; 197(8):619-22. PubMed ID: 19684500 [TBL] [Abstract][Full Text] [Related]
16. Long-term experience with citalopram in the treatment of adolescent OCD. Thomsen PH; Ebbesen C; Persson C J Am Acad Child Adolesc Psychiatry; 2001 Aug; 40(8):895-902. PubMed ID: 11501688 [TBL] [Abstract][Full Text] [Related]
17. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. Sevincok L; Topuz A J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120 [TBL] [Abstract][Full Text] [Related]
18. Obsessive-compulsive disorder and migraine with medication-overuse headache. Cupini LM; De Murtas M; Costa C; Mancini M; Eusebi P; Sarchielli P; Calabresi P Headache; 2009 Jul; 49(7):1005-13. PubMed ID: 19496831 [TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Colonna L; Andersen HF; Reines EH Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906 [TBL] [Abstract][Full Text] [Related]